Immuno-Oncology Research

Explore expression of your immuno-oncology biomarker in the context of tumor immune microenvironment using pathologist reviewed tissues & TMAs selected specifically for immuno-oncology projects.

TriStar offers a range TMAs (multi-tumor & tumor-specific) designed specifically for immuno-oncology projects with donors represented by cores taken from invasive margin and tumor center, created from FFPE blocks with associated TIL assessment (high/moderate/low) and PD-L1 scores (22C3).

Generate and compare immune profiles across multiple tumor types using established & optimized immune biomarker assays. Analyze tissues with extensive SOC & CKI clinical follow up information to integrate tumor immune profiles with treatment response & resistance.

Benefits of choosing Tristar’s services


TMAs designed for immuno-oncology projects with added immune cell infiltration data available, plus optional RNAseq data & 2nd line CKI treatment and response information.

Immune biomarker assays

Optimized assays for immune cell populations and pathologist/digital image analysis solutions for enumeration.

Service Workflow

Define Your Project Requirements
We will sit down with you and work out exactly what the objective of your project is as well as the parameters to work within.
Sample Allocation
We will source the right samples from within our repositories and network.
Services Platform
We will put together the right team and platforms to complete your project correctly and on time.
Confirm & Start Project
A Statement of Work that includes a project plan, deliverables, costs and timelines will be discussed and agreed upon.

Related Services

Enable Medicine AACR 2023 04/04/2023

Single-cell spatial proteomic analysis of the tumor microenvironment in treatment-naive NSCLC samples with immunotherapy treatment and response data.

The Mediterranean Institute of Oncology, Catania, Italy AACR 202004/04/2020

Opposing CD68/CD163 tumor immune microenvironments revealed using a large multi-tumor tissue microarray (TMA) comprising cores from invasive margin (IM) and tumor center (TC).